Fady I Malik
Fady I Malik is an expert in Cardiology at Cytokinetics (United States) (United States). As of October 2026, ScienceLeadR ranks Fady I Malik in the top 1% of experts worldwide for Aortic Valve Disease, Cardiomyopathies and Heart Failure. Fady I Malik has authored 203 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 2 of them ongoing. SLR score: 1,074 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Biochemistry - Rheumatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 203
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. PMID 42667274 — cardiomyopathy, hypertrophic, therapeutics, blood circulation, cardiomyopathies | Circulation Top journal | 2026 | 1 |
| Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM. PMID 42667283 — heart failure, cardiomyopathy, hypertrophic, therapeutics, metoprolol, cardiomyopathies | JACC Heart Fail | 2026 | 0 |
| Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM. PMID 42663111 — exercise, heart failure, diastolic, cardiomyopathy, hypertrophic, cardiac myosins, therapeutics, blood circulation, cardiomyopathies | Circulation Top journal | 2026 | 1 |
| Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. PMID 42663312 — health status, cardiomyopathy, hypertrophic, therapeutics, cardiomyopathies | N Engl J Med Top journal | 2026 | 5 |
| Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM. PMID 42544039 — heart failure, cardiomyopathy, hypertrophic, patient reported outcome measures, forests, cardiomyopathies | Eur J Heart Fail | 2026 | 1 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM) NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies | Phase 3 | Active not recruiting | 2023 |
| Open label Extension Study to Evaluate the Long term Safety and Tolerability of Aficamten in Adults With HCM NCT04848506 — safety, tablets, cardiomyopathy, hypertrophic, research, therapeutics, forests, cardiomyopathies | Phase 2/Phase 3 | Enrolling by invitation | 2021 |
LeadR Networks
Main global connection map